This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study
by Zacks Equity Research
Data from a late-stage study shows that transfusion-dependent thalassemia patients who received Agios' (AGIO) Pyrukynd demonstrated a statistically significant reduction in transfusion burden.
Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain cancer drug that was sold to Servier in 2021.
Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday
by Zacks Equity Research
Cytokinetics (CYTK) declines after announcing plans for raising about a billion dollars in funding.
Royalty Pharma (RPRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Royalty Pharma (RPRX) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 2.08% and 6.79%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Crescent Capital BDC (CCAP) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Crescent Capital BDC (CCAP) delivered earnings and revenue surprises of 6.78% and 4.25%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Royalty Pharma (RPRX)
by Zacks Equity Research
Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Insights Into Royalty Pharma (RPRX) Q1: Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Royalty Pharma (RPRX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Here's What to Expect From Assurant's (AIZ) Q1 Earnings
by Zacks Equity Research
Assurant's (AIZ) first-quarter performance is likely to have benefited from higher yields in fixed maturity securities, lender-placed average insured values and organic growth across all products.
Royalty Pharma (RPRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Royalty Pharma (RPRX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
RPRX or BX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
RPRX vs. BX: Which Stock Is the Better Value Option?
TEVA, Royalty Pharma Sign Funding Deal for Schizophrenia Drug
by Zacks Equity Research
Per the deal, Royalty Pharma is set to provide TEVA R&D funding support of up to $125 million to develop olanzapine LAI for treating schizophrenia.
Ryan Specialty Group (RYAN) Meets Q3 Earnings Estimates
by Zacks Equity Research
Ryan Specialty (RYAN) delivered earnings and revenue surprises of 0% and 0.20%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Houlihan Lokey (HLI) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Houlihan Lokey (HLI) delivered earnings and revenue surprises of 11% and 4.47%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Alerus (ALRS) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Alerus (ALRS) delivered earnings and revenue surprises of 32.35% and 3.83%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
RPRX vs. BAM: Which Stock Is the Better Value Option?
by Zacks Equity Research
RPRX vs. BAM: Which Stock Is the Better Value Option?
Compared to Estimates, Royalty Pharma (RPRX) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Royalty Pharma (RPRX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 2.41% and 1.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Royalty Pharma (RPRX) Might Surprise This Earnings Season
by Zacks Equity Research
Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Trupanion (TRUP) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Trupanion (TRUP) delivered earnings and revenue surprises of 21.43% and 3.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
PJT Partners (PJT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
PJT Partners (PJT) delivered earnings and revenue surprises of 54.69% and 41.92%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?